BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 11805868)

  • 1. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients].
    Stübiger N; Kötter I; Deuter C; Zierhut M
    Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
    Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
    Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.
    Kötter I; Eckstein AK; Stübiger N; Zierhut M
    Br J Ophthalmol; 1998 May; 82(5):488-94. PubMed ID: 9713053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
    Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
    Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
    Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
    Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of interferon alpha-2a therapy in patients with Behcet's disease.
    Yalçindağ FN; Uzun A
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial.
    Kötter I; Vonthein R; Zierhut M; Eckstein AK; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Stübiger N
    Semin Arthritis Rheum; 2004 Apr; 33(5):311-9. PubMed ID: 15079762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.
    Aydinoglu-Candan Ö; Araz-Erşan B; Gul A; Badur S; Tugal-Tutkun I
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):457-65. PubMed ID: 25500983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
    Park JY; Chung YR; Lee K; Song JH; Lee ES
    Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.
    Deuter CM; Zierhut M; Möhle A; Vonthein R; Stöbiger N; Kötter I
    Arthritis Rheum; 2010 Sep; 62(9):2796-805. PubMed ID: 20518075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
    Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
    Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments.
    Sobaci G; Erdem U; Durukan AH; Erdurman C; Bayer A; Köksal S; Karagul S; Bayraktar MZ
    Ophthalmology; 2010 Jul; 117(7):1430-5. PubMed ID: 20417563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease.
    Guillaume-Czitrom S; Berger C; Pajot C; Bodaghi B; Wechsler B; Kone-Paut I
    Rheumatology (Oxford); 2007 Oct; 46(10):1570-3. PubMed ID: 17702770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study.
    Hamuryudan V; Ozyazgan Y; Fresko Y; Mat C; Yurdakul S; Yazici H
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):928-30. PubMed ID: 12455182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
    Celiker H; Kazokoglu H; Direskeneli H
    Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.
    Wechsler B; Bodaghi B; Huong DL; Fardeau C; Amoura Z; Cassoux N; Piette JC; LeHoang P
    Ocul Immunol Inflamm; 2000 Dec; 8(4):293-301. PubMed ID: 11262659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease.
    Treusch M; Vonthein R; Baur M; Günaydin I; Koch S; Stübiger N; Eckstein AK; Peter HH; Ness T; Zierhut M; Kötter I
    Rheumatology (Oxford); 2004 Oct; 43(10):1275-82. PubMed ID: 15252211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azathioprine in severe uveitis of Behçet's disease.
    Saadoun D; Wechsler B; Terrada C; Hajage D; Le Thi Huong D; Resche-Rigon M; Cassoux N; Le Hoang P; Amoura Z; Bodaghi B; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1733-8. PubMed ID: 20665749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular cytokine patterns in Behçet's disease in comparison to ankylosing spondylitis--influence of treatment with interferon-alpha2a.
    Amberger M; Groll S; Günaydin I; Deuter C; Vonthein R; Kötter I
    Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S52-7. PubMed ID: 17949552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement.
    Kuemmerle-Deschner JB; Tzaribachev N; Deuter C; Zierhut M; Batra M; Koetter I
    Rheumatology (Oxford); 2008 Jul; 47(7):1051-3. PubMed ID: 18492711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.